Company intelligence / Profile preview

Supergene

Ownership: Private
Employees: ~90
Development stage: Phase 3

Overview

SuperGen developed Dacogen (decitabine) which was FDA-approved and marketed by Eisai in North America and Cilag GmbH International elsewhere. The company had multiple compounds in clinical development, with several in Phase 2 trials.

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

4 assets

pentostatin

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

GlaxoSmithKlineEisaiJohnson & JohnsonNovartisAstraZeneca

Beyond the preview

Go deeper on Supergene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Supergene.

Explore the full profile